Cargando…

The transcription factor KLF4 as an independent predictive marker for pathologic complete remission in breast cancer neoadjuvant chemotherapy: a case–control study

BACKGROUND: To identify whether a stem cell biomarker, KLF4, may predict the pathologic tumor response to neoadjuvant chemotherapy for patients with locally advanced breast cancer. METHODS: Twelve locally advanced breast cancer patients who achieved pathologic complete remission (pCR) after neoadjuv...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Min Jun, Wang, Lin Bo, Jiang, Zhi Nong, Jin, Mei, Hu, Wen Xian, Shen, Jian Guo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4216037/
https://www.ncbi.nlm.nih.gov/pubmed/25368523
http://dx.doi.org/10.2147/OTT.S68340
_version_ 1782342198971334656
author Dong, Min Jun
Wang, Lin Bo
Jiang, Zhi Nong
Jin, Mei
Hu, Wen Xian
Shen, Jian Guo
author_facet Dong, Min Jun
Wang, Lin Bo
Jiang, Zhi Nong
Jin, Mei
Hu, Wen Xian
Shen, Jian Guo
author_sort Dong, Min Jun
collection PubMed
description BACKGROUND: To identify whether a stem cell biomarker, KLF4, may predict the pathologic tumor response to neoadjuvant chemotherapy for patients with locally advanced breast cancer. METHODS: Twelve locally advanced breast cancer patients who achieved pathologic complete remission (pCR) after neoadjuvant chemotherapy were identified and for each, three non-pCR breast cancer patients – matched for age, clinical tumor–node–metastasis stage, and neoadjuvant chemotherapy cycles – were selected. The relationship between KLF4 expression in the core needle biopsied cancer tissue and patient pCR rate was assessed using univariate and multivariate analysis. RESULTS: Receiver operating characteristic curve analysis showed that the patients with a histoscore of KLF4 expression >0.18 had a lower pCR rate. Multivariable analysis showed that higher KLF4 expression (odds ratio 0.013; 95% confidence interval 0.013–0.444; P=0.004) was independently correlated with a lower pCR rate after neoadjuvant chemotherapy. CONCLUSION: KLF4 overexpression was associated with lower pCR in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy. This study suggests that KLF4 may serve as a predictor for pCR in patients with breast cancer after neoadjuvant chemotherapy.
format Online
Article
Text
id pubmed-4216037
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-42160372014-11-03 The transcription factor KLF4 as an independent predictive marker for pathologic complete remission in breast cancer neoadjuvant chemotherapy: a case–control study Dong, Min Jun Wang, Lin Bo Jiang, Zhi Nong Jin, Mei Hu, Wen Xian Shen, Jian Guo Onco Targets Ther Original Research BACKGROUND: To identify whether a stem cell biomarker, KLF4, may predict the pathologic tumor response to neoadjuvant chemotherapy for patients with locally advanced breast cancer. METHODS: Twelve locally advanced breast cancer patients who achieved pathologic complete remission (pCR) after neoadjuvant chemotherapy were identified and for each, three non-pCR breast cancer patients – matched for age, clinical tumor–node–metastasis stage, and neoadjuvant chemotherapy cycles – were selected. The relationship between KLF4 expression in the core needle biopsied cancer tissue and patient pCR rate was assessed using univariate and multivariate analysis. RESULTS: Receiver operating characteristic curve analysis showed that the patients with a histoscore of KLF4 expression >0.18 had a lower pCR rate. Multivariable analysis showed that higher KLF4 expression (odds ratio 0.013; 95% confidence interval 0.013–0.444; P=0.004) was independently correlated with a lower pCR rate after neoadjuvant chemotherapy. CONCLUSION: KLF4 overexpression was associated with lower pCR in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy. This study suggests that KLF4 may serve as a predictor for pCR in patients with breast cancer after neoadjuvant chemotherapy. Dove Medical Press 2014-10-24 /pmc/articles/PMC4216037/ /pubmed/25368523 http://dx.doi.org/10.2147/OTT.S68340 Text en © 2014 Dong et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Dong, Min Jun
Wang, Lin Bo
Jiang, Zhi Nong
Jin, Mei
Hu, Wen Xian
Shen, Jian Guo
The transcription factor KLF4 as an independent predictive marker for pathologic complete remission in breast cancer neoadjuvant chemotherapy: a case–control study
title The transcription factor KLF4 as an independent predictive marker for pathologic complete remission in breast cancer neoadjuvant chemotherapy: a case–control study
title_full The transcription factor KLF4 as an independent predictive marker for pathologic complete remission in breast cancer neoadjuvant chemotherapy: a case–control study
title_fullStr The transcription factor KLF4 as an independent predictive marker for pathologic complete remission in breast cancer neoadjuvant chemotherapy: a case–control study
title_full_unstemmed The transcription factor KLF4 as an independent predictive marker for pathologic complete remission in breast cancer neoadjuvant chemotherapy: a case–control study
title_short The transcription factor KLF4 as an independent predictive marker for pathologic complete remission in breast cancer neoadjuvant chemotherapy: a case–control study
title_sort transcription factor klf4 as an independent predictive marker for pathologic complete remission in breast cancer neoadjuvant chemotherapy: a case–control study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4216037/
https://www.ncbi.nlm.nih.gov/pubmed/25368523
http://dx.doi.org/10.2147/OTT.S68340
work_keys_str_mv AT dongminjun thetranscriptionfactorklf4asanindependentpredictivemarkerforpathologiccompleteremissioninbreastcancerneoadjuvantchemotherapyacasecontrolstudy
AT wanglinbo thetranscriptionfactorklf4asanindependentpredictivemarkerforpathologiccompleteremissioninbreastcancerneoadjuvantchemotherapyacasecontrolstudy
AT jiangzhinong thetranscriptionfactorklf4asanindependentpredictivemarkerforpathologiccompleteremissioninbreastcancerneoadjuvantchemotherapyacasecontrolstudy
AT jinmei thetranscriptionfactorklf4asanindependentpredictivemarkerforpathologiccompleteremissioninbreastcancerneoadjuvantchemotherapyacasecontrolstudy
AT huwenxian thetranscriptionfactorklf4asanindependentpredictivemarkerforpathologiccompleteremissioninbreastcancerneoadjuvantchemotherapyacasecontrolstudy
AT shenjianguo thetranscriptionfactorklf4asanindependentpredictivemarkerforpathologiccompleteremissioninbreastcancerneoadjuvantchemotherapyacasecontrolstudy
AT dongminjun transcriptionfactorklf4asanindependentpredictivemarkerforpathologiccompleteremissioninbreastcancerneoadjuvantchemotherapyacasecontrolstudy
AT wanglinbo transcriptionfactorklf4asanindependentpredictivemarkerforpathologiccompleteremissioninbreastcancerneoadjuvantchemotherapyacasecontrolstudy
AT jiangzhinong transcriptionfactorklf4asanindependentpredictivemarkerforpathologiccompleteremissioninbreastcancerneoadjuvantchemotherapyacasecontrolstudy
AT jinmei transcriptionfactorklf4asanindependentpredictivemarkerforpathologiccompleteremissioninbreastcancerneoadjuvantchemotherapyacasecontrolstudy
AT huwenxian transcriptionfactorklf4asanindependentpredictivemarkerforpathologiccompleteremissioninbreastcancerneoadjuvantchemotherapyacasecontrolstudy
AT shenjianguo transcriptionfactorklf4asanindependentpredictivemarkerforpathologiccompleteremissioninbreastcancerneoadjuvantchemotherapyacasecontrolstudy